Novartis upgrades mid-term sales growth guidance

 

• Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth

• Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers

• Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets

• Focused strategy and financial discipline has delivered robust sales, core operating income and free cash flow growth

• Industry-leading performance across priority ESG ratings and remain committed to creating value through focusing on material ESG factors

https://finance.yahoo.com/news/novartis-upgrades-mid-term-sales-060000704.html